![Eli Lilly headquarters](https://www.ibj.com/wp-content/uploads/2019/01/lilly-2col-300x200.jpg)
Lilly, Chinese firm to pursue therapies for metabolic disorders
Indianapolis-based Eli Lilly and Co. has inked a research collaboration and licensing agreement with Regor Therapeutics Group that could be worth up to $1.5 billion.
Indianapolis-based Eli Lilly and Co. has inked a research collaboration and licensing agreement with Regor Therapeutics Group that could be worth up to $1.5 billion.
The biggest policy change—a system for Medicare to negotiate prices for prescription drugs—won’t begin to deliver lower costs until 2025, and then only for a selected set of 10 medicines, as well as insulin products.
The purchase will amount to 614,000 doses of two drugs, bamlanivimab and etesevimab, that make up the drug-cocktail infusion, Lilly said.
The ruling from Senior Judge Sarah Evans Barker also hinted that Congress needs to address the problems with the 340B Drug Pricing Program.
Indianapolis-based Eli Lilly and Co. saw revenue in the third quarter increase 18 percent over the same period of 2020, to $6.77 billion.
“A cut [in drug prices] like is being proposed would have about a 40% reduction in our U.S. revenues,” Lilly CEO David Ricks said in a television interview this week with Gerry Dick on Inside Indiana Business, a division of IBJ Media.
The drugmaker’s COVID-19 treatment is back on the market after a two-month suspension, but the question is whether Lilly can grab market share from now-dominant Regeneron Pharmaceuticals.
Eli Lilly’s therapy has been shown to be highly effective against the delta variant, which is now the dominant strain of the coronavirus in the United States.
Two former job applicants, aged 55 and 49, filed a proposed class-action lawsuit in U.S. District Court in Indianapolis on Wednesday, accusing the Indianapolis-based drug maker of age discrimination.
Eli Lilly and Co. has produced at least two video commercials featuring Olympic swimmer Ryan Murphy promoting its migraine treatment, Emgality. But one of the ads contains a fleeting disclaimer: Murphy doesn’t take Emgality.
The mandate covers about 15,400 Lilly employees in numerous states and Puerto Rico, including about 11,000 in Indiana.
Eli Lilly and Co. turned in a profitable second quarter, but the results were shy of Wall Street analyst predictions. The drugmaker, however, saw revenue growth that topped Wall Street expectations.
Even as some drugmakers, including Indianapolis-based Eli Lilly and Co., are pushing to get experimental drugs approved, federal regulators are still dealing with a huge blowback over the controversial way they reviewed a new Alzheimer’s drug by rival Biogen.
The collaboration could be worth as much as $694 million and potential royalties to Verge Genomics if the two companies hit development milestones.
The role of the sticky substance in the brain has long divided researchers and is at the forefront again amid the FDA’s recent clearance of the first drug to treat the disease in almost two decades.
In her complaint, the lobbyist had claimed a top executive made sexist comments about her, mocked her physical appearance and subjected her and other women to a hostile work environment.
Eli Lilly and Co. shares jumped more than 9% Thursday morning after it received “breakthrough therapy” designation for donanemab from the U.S. Food and Drug Administration, putting the drug on a path that could expedite its development.
Mathilde Merlet oversees one of Eli Lilly and Co.’s fastest-growing products, a medicine called Taltz that treats a variety of dermatology and rheumatology disorders.
The use of COVID antibodies has fallen across the United States lately and, along with it, Lilly’s sales in that category.
Shares of Biogen competitors soared after aducanumab became the first drug cleared by the U.S. Food and Drug Administration to slow the course of the mind-wasting disease that afflicts 6 million Americans.